<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02268812</url>
  </required_header>
  <id_info>
    <org_study_id>SNX-111-E044-401</org_study_id>
    <nct_id>NCT02268812</nct_id>
  </id_info>
  <brief_title>Patient Registry of Intrathecal Pain Management in Europe for Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.</brief_title>
  <acronym>PRIME</acronym>
  <official_title>Patient Registry of Intrathecal Pain Management in Europe: An Open-label, Long-term, Multi-center, Multi-national Post-marketing Observational Study of the Use of Prialt (Ziconotide Intrathecal Infusion) and Alternative Drugs for the Management of Severe, Chronic Pain.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label, long-term, multi-center multi-national post-marketing observational
      registry. The objective of this study is to monitor the long-term efficacy, safety,
      tolerability and quality of life outcomes associated with ziconotide (Prialt) and other
      analgesics utilized in the intrathecal (IT) management of severe chronic pain.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an observational non-interventional registry. All patients will sign and date an
      Informed Consent Form (ICF) before enrollment (Baseline Visit). Normal clinical practice will
      be followed. Patients will continue to follow their usual schedule of clinic visits as
      determined by their physician, during which information and patient-completed questionnaires
      will be collected (at scheduled intervals timed to coincide with pump refill).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">July 2012</completion_date>
  <primary_completion_date type="Actual">July 2012</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Other</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Average Overall Change From Baseline (Visit 1) in Visual Analog Scale of Pain Intensity (VASPI)</measure>
    <time_frame>Month 8 (Visit 4), Month 12 (Visit 5), and Termination Visit (12 months after last participant was enrolled)</time_frame>
    <description>VASPI is a worldwide validated measure of pain intensity. A Visual Analog Score (VAS) for pain is determined by using a horizontal line, 100-millimeter (mm) in length, anchored by word descriptors at each end; &quot;no pain&quot; (0 mm) on the left end and &quot;worst imaginable pain&quot; (100 mm) on the right end. The participant was asked to mark on the line the point that they feel represents their current state of pain. A VAS for least pain (over last two weeks), usual pain (over last two weeks), and pain today was determined and averaged to derive the total VAS score ranging from 0 (no pain) to 100 (worst pain imaginable). A last observation carried forward (LOCF) dataset was used to account for missing data where First Visit data could be carried forward.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Change in Pain Severity and Pain Interference From Baseline (Visit 1) to Month 12 (Visit 5)</measure>
    <time_frame>Baseline (Visit 1) to Month 12 (Visit 5)</time_frame>
    <description>The Brief Pain Inventory-Short Form (BPI-SF) survey is made up of two dimensions: pain intensity/severity and pain interference, with each dimension containing specific items that are graded (e.g. mood, walking ability, relations with other people, enjoyment of life, etc.). Each item was graded on an 11-point Likert scale. The pain intensity/severity survey was used to measure pain severity, where 0 was &quot;no pain&quot; and 10 was &quot;pain as bad as you can imagine&quot; for each item listed. The pain interference survey scored each item on a scale, where 0 was &quot;does not interfere&quot; to 10 was &quot;completely interferes&quot;. The change in pain severity and pain interference from Baseline (Visit 1) were calculated from the scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Change in Pain Severity and Pain Interference From Baseline (Visit 1) to Termination Visit</measure>
    <time_frame>Baseline (Visit 1) to Termination Visit (12 Months after last participant was enrolled)</time_frame>
    <description>The BPI-SF survey is made up of two dimensions: pain intensity/severity and pain interference, with each dimension containing specific items that are graded (e.g. mood, walking ability, relations with other people, enjoyment of life, etc.). Each item was graded on an 11-point Likert scale. The pain intensity/severity survey was used to measure pain severity, where 0 was &quot;no pain&quot; and 10 was &quot;pain as bad as you can imagine&quot; for each item listed. The pain interference survey scored each item on a scale, where 0 was &quot;does not interfere&quot; to 10 was &quot;completely interferes&quot;. The change in pain severity and pain interference from Baseline (Visit 1) were calculated from the scores.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)</measure>
    <time_frame>From first dose up to 30 days after the last dose of study treatment, for up to approximately 4 years 4 months.</time_frame>
    <description>Safety assessments consisted of monitoring and recording all adverse events (AEs) and serious adverse events (SAEs), any therapeutic interventions including all drug therapies, vital signs, and creatine kinase (CK) if laboratory tests were taken by the physician as part of routine clinical practice. AEs were graded on a 3-point scale; 1) mild - discomfort noticed, but no disruption of normal daily activity, 2) moderate - discomfort sufficient to reduce or affect normal daily activity, 3) severe - incapacitating, with inability to work or to perform normal daily activity. A TEAE was defined as an adverse event (AE) with a start date on or after the date of the First Visit. Where a start date was missing, the AE was considered to be treatment-emergent.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Changes in Primary Intrathecal Drug, Including Dose Adjustment and Intervals</measure>
    <time_frame>12 months after the last patient was enrolled</time_frame>
    <description>Data for this outcome measure was collected as part of the participant's study visit, however was not analyzed as an efficacy endpoint for reporting.</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in the Actual Overall EuroQoL (EQ-5D) Health Score From First Visit to Month 12 and End of Study</measure>
    <time_frame>Month 12 Visit, End of Study (Termination Visit)</time_frame>
    <description>The EQ-5D is a standardized instrument used to measure quality of life. It classifies health states across five domains: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each domain has three levels (no problems, some/moderate problems, extreme problems). A unique EQ-5D health state was defined by combining one level from each of the five dimensions. The response to the question of how good or bad the participant's health was today was given on a visual analogue scale of 0 to 100 millimeters (mm), where 0 meant the participant was in the worst imaginable health state today and 100 meant the participant was in the best imaginable health state today. The results for the Health Score were that of the calculated overall score of the five dimensions, where -0.594 is worst health and 1.00 is perfect health. Change is defined as change in actual from the First Visit.</description>
  </other_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">219</enrollment>
  <condition>Pain Management</condition>
  <condition>Severe Chronic Pain</condition>
  <arm_group>
    <arm_group_label>Ziconotide</arm_group_label>
    <description>No drug will be provided by the sponsor. Treatment decisions will be made by physicians independent of participation in the registry.
IT analgesia may consist of ziconotide or any other drug used in IT therapy, including those used off-label as part of local clinical practice.</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patients that have a diagnosis of severe, chronic pain for which intrathecal infusion is
        indicated.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria

        Patients will be eligible to enroll onto the registry if they have given informed consent
        and meet the following criteria:

          -  Patient's physician has deemed that the initiation/switch of intrathecal analgesia
             appropriate, or patient is presently utilizing ziconotide (Prialt)

          -  Patient has a diagnosis of severe, chronic pain for which intrathecal infusion is
             indicated

          -  Patient is at least 18 years of age at time of study entry

        All patients starting ziconotide (Prialt) should comply with the indications and warnings
        in the current approved version of the Summary of Product Characteristics (SmPC).

        Exclusion Criteria

        Patients who meet any of the following criteria will not be eligible to enroll in the
        registry:

          -  Patient is a pregnant or lactating female

          -  Patient is receiving intrathecal chemotherapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>January 2018</verification_date>
  <study_first_submitted>October 16, 2014</study_first_submitted>
  <study_first_submitted_qc>October 16, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2014</study_first_posted>
  <results_first_submitted>January 18, 2017</results_first_submitted>
  <results_first_submitted_qc>January 5, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">October 25, 2018</results_first_posted>
  <last_update_submitted>January 5, 2018</last_update_submitted>
  <last_update_submitted_qc>January 5, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Pain Management</keyword>
  <keyword>Europe</keyword>
  <keyword>Intrathecal</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Chronic Pain</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ziconotide Monotherapy</title>
          <description>Participants who took ziconotide alone.</description>
        </group>
        <group group_id="P2">
          <title>Ziconotide Combination</title>
          <description>Participants who took ziconotide in combination with another intrathecal (IT) therapy.</description>
        </group>
        <group group_id="P3">
          <title>Other IT Monotherapy</title>
          <description>Participants who took an IT therapy other than ziconotide.</description>
        </group>
        <group group_id="P4">
          <title>Other IT Combination</title>
          <description>Participants who took two (or more) IT therapies in conjunction other than ziconotide.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="77"/>
                <participants group_id="P2" count="72"/>
                <participants group_id="P3" count="30"/>
                <participants group_id="P4" count="40"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="61"/>
                <participants group_id="P2" count="40"/>
                <participants group_id="P3" count="21"/>
                <participants group_id="P4" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="32"/>
                <participants group_id="P3" count="9"/>
                <participants group_id="P4" count="14"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="26"/>
                <participants group_id="P3" count="7"/>
                <participants group_id="P4" count="10"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Protocol deviation</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Physician Decision</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="1"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="1"/>
                <participants group_id="P4" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety population consisted of all participants who had at least one dose of an intrathecal (IT) therapy.</population>
      <group_list>
        <group group_id="B1">
          <title>Ziconotide Monotherapy</title>
          <description>Participants who took ziconotide alone.</description>
        </group>
        <group group_id="B2">
          <title>Ziconotide Combination</title>
          <description>Participants who took ziconotide in combination with another intrathecal (IT) therapy.</description>
        </group>
        <group group_id="B3">
          <title>Other IT Monotherapy</title>
          <description>Participants who took an IT therapy other than ziconotide.</description>
        </group>
        <group group_id="B4">
          <title>Other IT Combination</title>
          <description>Participants who took two (or more) IT therapies in conjunction other than ziconotide.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="77"/>
            <count group_id="B2" value="72"/>
            <count group_id="B3" value="30"/>
            <count group_id="B4" value="40"/>
            <count group_id="B5" value="219"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="53.2" spread="11.56"/>
                    <measurement group_id="B2" value="55.9" spread="13.46"/>
                    <measurement group_id="B3" value="56.7" spread="12.78"/>
                    <measurement group_id="B4" value="54.4" spread="11.69"/>
                    <measurement group_id="B5" value="54.8" spread="12.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="28"/>
                    <measurement group_id="B3" value="11"/>
                    <measurement group_id="B4" value="18"/>
                    <measurement group_id="B5" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="19"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="130"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Average Overall Change From Baseline (Visit 1) in Visual Analog Scale of Pain Intensity (VASPI)</title>
        <description>VASPI is a worldwide validated measure of pain intensity. A Visual Analog Score (VAS) for pain is determined by using a horizontal line, 100-millimeter (mm) in length, anchored by word descriptors at each end; &quot;no pain&quot; (0 mm) on the left end and &quot;worst imaginable pain&quot; (100 mm) on the right end. The participant was asked to mark on the line the point that they feel represents their current state of pain. A VAS for least pain (over last two weeks), usual pain (over last two weeks), and pain today was determined and averaged to derive the total VAS score ranging from 0 (no pain) to 100 (worst pain imaginable). A last observation carried forward (LOCF) dataset was used to account for missing data where First Visit data could be carried forward.</description>
        <time_frame>Month 8 (Visit 4), Month 12 (Visit 5), and Termination Visit (12 months after last participant was enrolled)</time_frame>
        <population>Intent-to-Treat (ITT) (LOCF) population included all participants who had at least one dose of an IT therapy. Total number of participants for the outcome measures (335) does not match the total number enrolled (219) due to participants switching between treatment arms as allowed per protocol.</population>
        <group_list>
          <group group_id="O1">
            <title>Ziconotide Monotherapy</title>
            <description>Participants who took ziconotide alone.</description>
          </group>
          <group group_id="O2">
            <title>Ziconotide Combination</title>
            <description>Participants who took ziconotide in combination with another intrathecal (IT) therapy.</description>
          </group>
          <group group_id="O3">
            <title>Other IT Monotherapy</title>
            <description>Participants who took an IT therapy other than ziconotide.</description>
          </group>
          <group group_id="O4">
            <title>Other IT Combination</title>
            <description>Participants who took two (or more) IT therapies in conjunction other than ziconotide.</description>
          </group>
        </group_list>
        <measure>
          <title>Average Overall Change From Baseline (Visit 1) in Visual Analog Scale of Pain Intensity (VASPI)</title>
          <description>VASPI is a worldwide validated measure of pain intensity. A Visual Analog Score (VAS) for pain is determined by using a horizontal line, 100-millimeter (mm) in length, anchored by word descriptors at each end; &quot;no pain&quot; (0 mm) on the left end and &quot;worst imaginable pain&quot; (100 mm) on the right end. The participant was asked to mark on the line the point that they feel represents their current state of pain. A VAS for least pain (over last two weeks), usual pain (over last two weeks), and pain today was determined and averaged to derive the total VAS score ranging from 0 (no pain) to 100 (worst pain imaginable). A last observation carried forward (LOCF) dataset was used to account for missing data where First Visit data could be carried forward.</description>
          <population>Intent-to-Treat (ITT) (LOCF) population included all participants who had at least one dose of an IT therapy. Total number of participants for the outcome measures (335) does not match the total number enrolled (219) due to participants switching between treatment arms as allowed per protocol.</population>
          <units>Units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 8 (Visit 4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.23" spread="23.160"/>
                    <measurement group_id="O2" value="-15.24" spread="23.614"/>
                    <measurement group_id="O3" value="-1.50" spread="20.736"/>
                    <measurement group_id="O4" value="-18.40" spread="21.899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Month 12 (Visit 5)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.78" spread="23.424"/>
                    <measurement group_id="O2" value="-9.33" spread="30.039"/>
                    <measurement group_id="O3" value="1.67" spread="20.894"/>
                    <measurement group_id="O4" value="-14.33" spread="29.800"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Termination Visit</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.01" spread="23.220"/>
                    <measurement group_id="O2" value="0.65" spread="28.208"/>
                    <measurement group_id="O3" value="1.64" spread="21.643"/>
                    <measurement group_id="O4" value="-14.27" spread="34.620"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Change in Pain Severity and Pain Interference From Baseline (Visit 1) to Month 12 (Visit 5)</title>
        <description>The Brief Pain Inventory-Short Form (BPI-SF) survey is made up of two dimensions: pain intensity/severity and pain interference, with each dimension containing specific items that are graded (e.g. mood, walking ability, relations with other people, enjoyment of life, etc.). Each item was graded on an 11-point Likert scale. The pain intensity/severity survey was used to measure pain severity, where 0 was &quot;no pain&quot; and 10 was &quot;pain as bad as you can imagine&quot; for each item listed. The pain interference survey scored each item on a scale, where 0 was &quot;does not interfere&quot; to 10 was &quot;completely interferes&quot;. The change in pain severity and pain interference from Baseline (Visit 1) were calculated from the scores.</description>
        <time_frame>Baseline (Visit 1) to Month 12 (Visit 5)</time_frame>
        <population>ITT LOCF population</population>
        <group_list>
          <group group_id="O1">
            <title>Ziconotide Monotherapy</title>
            <description>Participants who took ziconotide alone.</description>
          </group>
          <group group_id="O2">
            <title>Ziconotide Combination</title>
            <description>Participants who took ziconotide in combination with another intrathecal (IT) therapy.</description>
          </group>
          <group group_id="O3">
            <title>Other IT Monotherapy</title>
            <description>Participants who took an IT therapy other than ziconotide.</description>
          </group>
          <group group_id="O4">
            <title>Other IT Combination</title>
            <description>Participants who took two (or more) IT therapies in conjunction other than ziconotide.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Change in Pain Severity and Pain Interference From Baseline (Visit 1) to Month 12 (Visit 5)</title>
          <description>The Brief Pain Inventory-Short Form (BPI-SF) survey is made up of two dimensions: pain intensity/severity and pain interference, with each dimension containing specific items that are graded (e.g. mood, walking ability, relations with other people, enjoyment of life, etc.). Each item was graded on an 11-point Likert scale. The pain intensity/severity survey was used to measure pain severity, where 0 was &quot;no pain&quot; and 10 was &quot;pain as bad as you can imagine&quot; for each item listed. The pain interference survey scored each item on a scale, where 0 was &quot;does not interfere&quot; to 10 was &quot;completely interferes&quot;. The change in pain severity and pain interference from Baseline (Visit 1) were calculated from the scores.</description>
          <population>ITT LOCF population</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.41" spread="1.768"/>
                    <measurement group_id="O2" value="-0.77" spread="2.150"/>
                    <measurement group_id="O3" value="-0.09" spread="1.741"/>
                    <measurement group_id="O4" value="-0.99" spread="1.866"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain interference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.52" spread="1.645"/>
                    <measurement group_id="O2" value="-0.42" spread="2.445"/>
                    <measurement group_id="O3" value="-0.43" spread="2.248"/>
                    <measurement group_id="O4" value="-0.33" spread="2.039"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Change in Pain Severity and Pain Interference From Baseline (Visit 1) to Termination Visit</title>
        <description>The BPI-SF survey is made up of two dimensions: pain intensity/severity and pain interference, with each dimension containing specific items that are graded (e.g. mood, walking ability, relations with other people, enjoyment of life, etc.). Each item was graded on an 11-point Likert scale. The pain intensity/severity survey was used to measure pain severity, where 0 was &quot;no pain&quot; and 10 was &quot;pain as bad as you can imagine&quot; for each item listed. The pain interference survey scored each item on a scale, where 0 was &quot;does not interfere&quot; to 10 was &quot;completely interferes&quot;. The change in pain severity and pain interference from Baseline (Visit 1) were calculated from the scores.</description>
        <time_frame>Baseline (Visit 1) to Termination Visit (12 Months after last participant was enrolled)</time_frame>
        <population>ITT LOCF population</population>
        <group_list>
          <group group_id="O1">
            <title>Ziconotide Monotherapy</title>
            <description>Participants who took ziconotide alone.</description>
          </group>
          <group group_id="O2">
            <title>Ziconotide Combination</title>
            <description>Participants who took ziconotide in combination with another intrathecal (IT) therapy.</description>
          </group>
          <group group_id="O3">
            <title>Other IT Monotherapy</title>
            <description>Participants who took an IT therapy other than ziconotide.</description>
          </group>
          <group group_id="O4">
            <title>Other IT Combination</title>
            <description>Participants who took two (or more) IT therapies in conjunction other than ziconotide.</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Change in Pain Severity and Pain Interference From Baseline (Visit 1) to Termination Visit</title>
          <description>The BPI-SF survey is made up of two dimensions: pain intensity/severity and pain interference, with each dimension containing specific items that are graded (e.g. mood, walking ability, relations with other people, enjoyment of life, etc.). Each item was graded on an 11-point Likert scale. The pain intensity/severity survey was used to measure pain severity, where 0 was &quot;no pain&quot; and 10 was &quot;pain as bad as you can imagine&quot; for each item listed. The pain interference survey scored each item on a scale, where 0 was &quot;does not interfere&quot; to 10 was &quot;completely interferes&quot;. The change in pain severity and pain interference from Baseline (Visit 1) were calculated from the scores.</description>
          <population>ITT LOCF population</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Pain severity</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.27" spread="2.219"/>
                    <measurement group_id="O2" value="-1.11" spread="2.127"/>
                    <measurement group_id="O3" value="-0.04" spread="1.957"/>
                    <measurement group_id="O4" value="-0.74" spread="2.321"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain interference</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.77" spread="2.809"/>
                    <measurement group_id="O2" value="-1.05" spread="2.798"/>
                    <measurement group_id="O3" value="-0.73" spread="1.718"/>
                    <measurement group_id="O4" value="-0.72" spread="2.054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)</title>
        <description>Safety assessments consisted of monitoring and recording all adverse events (AEs) and serious adverse events (SAEs), any therapeutic interventions including all drug therapies, vital signs, and creatine kinase (CK) if laboratory tests were taken by the physician as part of routine clinical practice. AEs were graded on a 3-point scale; 1) mild - discomfort noticed, but no disruption of normal daily activity, 2) moderate - discomfort sufficient to reduce or affect normal daily activity, 3) severe - incapacitating, with inability to work or to perform normal daily activity. A TEAE was defined as an adverse event (AE) with a start date on or after the date of the First Visit. Where a start date was missing, the AE was considered to be treatment-emergent.</description>
        <time_frame>From first dose up to 30 days after the last dose of study treatment, for up to approximately 4 years 4 months.</time_frame>
        <population>Safety population included all participants who had at least one dose of an IT therapy.</population>
        <group_list>
          <group group_id="O1">
            <title>Ziconotide Monotherapy</title>
            <description>Participants who took ziconotide alone.</description>
          </group>
          <group group_id="O2">
            <title>Ziconotide Combination</title>
            <description>Participants who took ziconotide in combination with another intrathecal (IT) therapy.</description>
          </group>
          <group group_id="O3">
            <title>Other IT Monotherapy</title>
            <description>Participants who took an IT therapy other than ziconotide.</description>
          </group>
          <group group_id="O4">
            <title>Other IT Combination</title>
            <description>Participants who took two (or more) IT therapies in conjunction other than ziconotide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants Who Experienced at Least One Treatment-Emergent Adverse Event (TEAE)</title>
          <description>Safety assessments consisted of monitoring and recording all adverse events (AEs) and serious adverse events (SAEs), any therapeutic interventions including all drug therapies, vital signs, and creatine kinase (CK) if laboratory tests were taken by the physician as part of routine clinical practice. AEs were graded on a 3-point scale; 1) mild - discomfort noticed, but no disruption of normal daily activity, 2) moderate - discomfort sufficient to reduce or affect normal daily activity, 3) severe - incapacitating, with inability to work or to perform normal daily activity. A TEAE was defined as an adverse event (AE) with a start date on or after the date of the First Visit. Where a start date was missing, the AE was considered to be treatment-emergent.</description>
          <population>Safety population included all participants who had at least one dose of an IT therapy.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Any TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="66"/>
                    <measurement group_id="O2" value="88"/>
                    <measurement group_id="O3" value="46"/>
                    <measurement group_id="O4" value="48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="56"/>
                    <measurement group_id="O2" value="54"/>
                    <measurement group_id="O3" value="26"/>
                    <measurement group_id="O4" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="26"/>
                    <measurement group_id="O2" value="51"/>
                    <measurement group_id="O3" value="24"/>
                    <measurement group_id="O4" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="9"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs leading to death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="26"/>
                    <measurement group_id="O3" value="7"/>
                    <measurement group_id="O4" value="12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Changes in Primary Intrathecal Drug, Including Dose Adjustment and Intervals</title>
        <description>Data for this outcome measure was collected as part of the participant's study visit, however was not analyzed as an efficacy endpoint for reporting.</description>
        <time_frame>12 months after the last patient was enrolled</time_frame>
        <population>Data for this outcome measure was collected as part of the participant's study visit, however was not analyzed as an efficacy endpoint for reporting.</population>
        <group_list>
          <group group_id="O1">
            <title>Ziconotide Monotherapy</title>
            <description>Participants who took ziconotide alone.</description>
          </group>
          <group group_id="O2">
            <title>Ziconotide Combination</title>
            <description>Participants who took ziconotide in combination with another intrathecal (IT) therapy.</description>
          </group>
          <group group_id="O3">
            <title>Other IT Monotherapy</title>
            <description>Participants who took an IT therapy other than ziconotide.</description>
          </group>
          <group group_id="O4">
            <title>Other IT Combination</title>
            <description>Participants who took two (or more) IT therapies in conjunction other than ziconotide.</description>
          </group>
        </group_list>
        <measure>
          <title>Changes in Primary Intrathecal Drug, Including Dose Adjustment and Intervals</title>
          <description>Data for this outcome measure was collected as part of the participant's study visit, however was not analyzed as an efficacy endpoint for reporting.</description>
          <population>Data for this outcome measure was collected as part of the participant's study visit, however was not analyzed as an efficacy endpoint for reporting.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
                <count group_id="O3" value="0"/>
                <count group_id="O4" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Other Pre-specified</type>
        <title>Change in the Actual Overall EuroQoL (EQ-5D) Health Score From First Visit to Month 12 and End of Study</title>
        <description>The EQ-5D is a standardized instrument used to measure quality of life. It classifies health states across five domains: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each domain has three levels (no problems, some/moderate problems, extreme problems). A unique EQ-5D health state was defined by combining one level from each of the five dimensions. The response to the question of how good or bad the participant's health was today was given on a visual analogue scale of 0 to 100 millimeters (mm), where 0 meant the participant was in the worst imaginable health state today and 100 meant the participant was in the best imaginable health state today. The results for the Health Score were that of the calculated overall score of the five dimensions, where -0.594 is worst health and 1.00 is perfect health. Change is defined as change in actual from the First Visit.</description>
        <time_frame>Month 12 Visit, End of Study (Termination Visit)</time_frame>
        <population>ITT population. Missing items/values used in calculating the partially complete Health Score were imputed using last observation carried forward (LOCF).</population>
        <group_list>
          <group group_id="O1">
            <title>Ziconotide Monotherapy</title>
            <description>Participants who took ziconotide alone.</description>
          </group>
          <group group_id="O2">
            <title>Ziconotide Combination</title>
            <description>Participants who took ziconotide in combination with another intrathecal (IT) therapy.</description>
          </group>
          <group group_id="O3">
            <title>Other IT Monotherapy</title>
            <description>Participants who took an IT therapy other than ziconotide.</description>
          </group>
          <group group_id="O4">
            <title>Other IT Combination</title>
            <description>Participants who took two (or more) IT therapies in conjunction other than ziconotide.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in the Actual Overall EuroQoL (EQ-5D) Health Score From First Visit to Month 12 and End of Study</title>
          <description>The EQ-5D is a standardized instrument used to measure quality of life. It classifies health states across five domains: mobility, self-care, usual activities, pain/discomfort, anxiety/depression. Each domain has three levels (no problems, some/moderate problems, extreme problems). A unique EQ-5D health state was defined by combining one level from each of the five dimensions. The response to the question of how good or bad the participant's health was today was given on a visual analogue scale of 0 to 100 millimeters (mm), where 0 meant the participant was in the worst imaginable health state today and 100 meant the participant was in the best imaginable health state today. The results for the Health Score were that of the calculated overall score of the five dimensions, where -0.594 is worst health and 1.00 is perfect health. Change is defined as change in actual from the First Visit.</description>
          <population>ITT population. Missing items/values used in calculating the partially complete Health Score were imputed using last observation carried forward (LOCF).</population>
          <units>Scores on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="83"/>
                <count group_id="O2" value="114"/>
                <count group_id="O3" value="67"/>
                <count group_id="O4" value="71"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Month 12</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="21"/>
                    <count group_id="O2" value="12"/>
                    <count group_id="O3" value="15"/>
                    <count group_id="O4" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.01" spread="0.176"/>
                    <measurement group_id="O2" value="-0.06" spread="0.207"/>
                    <measurement group_id="O3" value="0.01" spread="0.217"/>
                    <measurement group_id="O4" value="-0.01" spread="0.136"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>End of Study</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="33"/>
                    <count group_id="O2" value="15"/>
                    <count group_id="O3" value="22"/>
                    <count group_id="O4" value="22"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.00" spread="0.196"/>
                    <measurement group_id="O2" value="0.04" spread="0.180"/>
                    <measurement group_id="O3" value="-0.03" spread="0.193"/>
                    <measurement group_id="O4" value="-0.02" spread="0.145"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>For each participant, from the first dose till 30 days after the last dose or up to the termination visit (which was 12 months after the last subject had been enrolled), or approximately 4 years.</time_frame>
      <desc>The safety population included all participants who received at least one dose of an IT therapy. Treatment emergent adverse events (TEAEs) and serious adverse events were reported. Participants could switch IT therapies during the study, so AEs were assigned to the treatment taken at the time and date of the onset of the AE. This resulted in the possibility of a participant being counted in more than one therapy category.</desc>
      <group_list>
        <group group_id="E1">
          <title>Ziconotide Monotherapy</title>
          <description>Participants who took ziconotide alone.</description>
        </group>
        <group group_id="E2">
          <title>Ziconotide Combination</title>
          <description>Participants who took ziconotide in combination with another intrathecal (IT) therapy.</description>
        </group>
        <group group_id="E3">
          <title>Other IT Monotherapy</title>
          <description>Participants who took an IT therapy other than ziconotide.</description>
        </group>
        <group group_id="E4">
          <title>Other IT Combination</title>
          <description>Participants who took two (or more) IT therapies in conjunction other than ziconotide.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="26" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="12" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="51" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="24" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="30" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Atrial Fibrillation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Left Ventricular Dysfunction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Left Ventricular Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Cataract</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Diplopia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Strabismus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Colitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Melaena</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Oesophagitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Subileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="7" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>General Physical Health Deterioration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Catheter Related Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Chest Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Catheter Site Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Disease Progression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Drug Withdrawal Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Extravasation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Face Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Generalised Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Infusion Site Mass</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Oedema</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Biliary Dilatation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Behcet's Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypersensitivity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Meningitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Catheter Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Device Related Infection</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Breast Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Escherichia Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Gastroenteritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Implant Site Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Lobar Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Lower Respiratory Tract Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Rectal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Soft Tissue Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Staphylococcal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Staphylococcal Skin Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Wound Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Medical Device Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Device Dislocation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hip Fracture</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Excoriation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Overdose</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Alcohol Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Device Connection Issue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Foot Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Inadequate Analgesia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Poisoning</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Road Traffic Accident</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Suture Related Complication</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Thermal Burn</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Thoracic Vertebral Fracture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Wound Secretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>C-reactive Protein Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>International Normalised Ratio Increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Feeding Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hyperglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypoalbuminaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Malnutrition</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Bone Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Foot Deformity</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Groin Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Intervertebral Disc Protrusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pseudarthrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Rotator Cuff Syndrome</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Spinal Column Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lung Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Neoplasm Malignant</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Breast Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Colorectal Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Non-small Cell Lung Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pancreatic Carcinoma Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Bone Sarcoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Colorectal Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Malignant Melanoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Metastases To Bone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Metastases To Central Nervous System</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Metastases To Meninges</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Metastatic Malignant Melanoma</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Metastatic Uterine Cancer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pancreatic Neoplasm</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Renal Cancer Metastatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cerebral Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dysgeusia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Head Titubation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypersomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Ischaemic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Nystagmus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Parosmia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Sciatica</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Speech Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Spinal Cord Compression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Stupor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Syncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Tremor</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Trigeminal Neuralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Depression</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hallucination</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Mental Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Agitation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Anxiety Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Delirium</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Drug Abuse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hallucinations, Mixed</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hostility</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Narcissistic Personality Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Psychotic Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Suicidal Ideation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Renal Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ovarian Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pelvic Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Prostatitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Acute Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Asphyxia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Bronchial Secretion Retention</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Obstructive Airways Disorder</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pulmonary Embolism</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Skin Erosion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Central Venous Catheterisation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Drug Therapy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Medical Device Removal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Nerve Block</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Peripheral Nerve Decompression</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Spinal Nerve Stimulator Implantation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Deep Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Shock Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Circulatory Collapse</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Peripheral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Venous Occlusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (11.1)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="59" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="34" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="43" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Vertigo</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="10" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="10" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Dry Mouth</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="6" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Weight Decreased</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Muscular Weakness</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Pain In Extremity</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="8" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Memory Impairment</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="4" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Hypoaesthesia</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Confusional State</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="71"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperhidrosis</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="83"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="114"/>
                <counts group_id="E3" subjects_affected="9" subjects_at_risk="67"/>
                <counts group_id="E4" subjects_affected="7" subjects_at_risk="71"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Eisai Medical Services</name_or_title>
      <organization>Eisai Europe Ltd.</organization>
      <phone>+44 (0)20 8600 1400</phone>
    </point_of_contact>
  </clinical_results>
</clinical_study>

